EUVIMEDScopri EUVIMED
Übersichtsarbeit

Neuroprotective Effects of Esketamine in Central Nervous System Disorders: Mechanisms and Cellular Targets

Chendi Zhao, Yan Wang, Jinglang Wu, Hong Cheng iD

Basic & Clinical Pharmacology & Toxicology · 2026

DOI: 10.1111/bcpt.70221 ↗

At a glance

Übersichtsarbeit in Basic & Clinical Pharmacology & Toxicology, 2026. Written by Chendi Zhao and 3 co-authors. Institution: Department of Anesthesiology, Affiliated Hospital of Hebei University, Baoding, Hebei, China. Major MEDLINE topics: Neuroprotective Agents, Central Nervous System Diseases, Ketamine. Cited 4 times so far (Crossref); 167 references. Funded by: Science and Technology Plan Project of Baoding.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Esketamine (ESK), the dextrorotatory enantiomer of ketamine, is an antagonist of the N‐methyl‐D‐aspartic acid (NMDA) receptor. ESK is considered an effective anesthetic because of its ability to mitigate postoperative pain and opioid use. Recently, it has attracted significant research attention for its fast‐acting antidepressant effects. Given the advantages of ESK in both perioperative and postoperative contexts, foundational research into this molecule is progressively moving forward. Accumulating evidence suggests that ESK possesses anti‐inflammatory, antiapoptotic and antioxidant characteristics in various diseases. This review summarizes the neuroprotective effects of ESK in central nervous system (CNS) disorders. ESK‐mediated cellular processes, including neuronal apoptosis, microglial polarization and astrocytic functions, are also summarized. In addition, the underlying molecular mechanisms of ESK are discussed, with a focus on inflammatory pathways and signalling cascades in neurological disorders.

Subjects

MeSH terms (MEDLINE)

Neuroprotective AgentsCentral Nervous System DiseasesKetamineHumansAnimalsReceptors, N-Methyl-D-AspartateSignal TransductionApoptosisNeuronsAntioxidantsAnti-Inflammatory Agents

Author keywords

central nervous systemesketamineinflammationneuroprotectionsignalling pathway

Substances

Neuroprotective AgentsKetamineReceptors, N-Methyl-D-AspartateEsketamineAntioxidantsAnti-Inflammatory Agents

Authors and institutions

  • Department of Anesthesiology, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
  • Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding, Hebei, China.

ORCID profiles: Hong Cheng

Funding

  • Science and Technology Plan Project of Baoding

Cite

APA

Zhao, C., Wang, Y., Wu, J., & Cheng, H. (2026). Neuroprotective Effects of Esketamine in Central Nervous System Disorders: Mechanisms and Cellular Targets. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70221

Vancouver

Zhao C, Wang Y, Wu J, Cheng H. Neuroprotective Effects of Esketamine in Central Nervous System Disorders: Mechanisms and Cellular Targets. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70221

BibTeX
@article{Zhao2026,
  author = {Zhao, Chendi and Wang, Yan and Wu, Jinglang and Cheng, Hong},
  title = {Neuroprotective Effects of Esketamine in Central Nervous System Disorders: Mechanisms and Cellular Targets},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2026},
  doi = {10.1111/bcpt.70221}
}
Start for free →